Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nicola Ferri, Alberto Corsini, Cesare Sirtori & Massimiliano Ruscica. (2017) PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs 26:5, pages 593-602.
Read now
Read now
Chek Kun Tan, Yan Zhuang & Walter Wahli. (2017) Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome. Expert Opinion on Therapeutic Targets 21:3, pages 333-348.
Read now
Read now
Areej Abuhammad & Mutasem O. Taha. (2016) QSAR studies in the discovery of novel type-II diabetic therapies. Expert Opinion on Drug Discovery 11:2, pages 197-214.
Read now
Read now
Articles from other publishers (36)
M. S. Afanamol, A. Deepika Dinesh, K. Shifa Ali, Ajeesh Vengamthodi & Arun Rasheed. (2023) Drug repurposing by in silico prediction of cyclizine derivatives as antihyperlipemic agents. In Silico Pharmacology 11:1.
Crossref
Crossref
Cen Xiang, Xiaoxuan Chen, Jiaping Yao, Na Yang, Jiajia Yu, Quanyuan Qiu, Shouqing Zhang, Xiangsun Kong, Lianbo Zhao, Zhen-Chuan Fan, Peng Yu & Yu-ou Teng. (2023) Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo. European Journal of Medicinal Chemistry 257, pages 115510.
Crossref
Crossref
Manoj Kumar Gupta, Gayatri Gouda, Sumreen Sultana, Shital Manohar Punekar, Ramakrishna Vadde & Tekupalli Ravikiran. 2023.
241
295
.
Junqiang J. Tian, Mark Levy, Xuekai Zhang, Robert Sinnott & Rolando Maddela. (2022) Counteracting health risks by Modulating Homeostatic Signaling. Pharmacological Research 182, pages 106281.
Crossref
Crossref
Mayumi Yamaguchi, Takeharu Asano, Takahiro Arisaka, Hirosato Mashima, Atsushi Irisawa & Masaya Tamano. (2022) Effects of pemafibrate on primary biliary cholangitis with dyslipidemia. Hepatology Research 52:6, pages 522-531.
Crossref
Crossref
Tong Wu, Guijuan Luo, Qiuyu Lian, Chengjun Sui, Jing Tang, Yanjing Zhu, Bo Zheng, Zhixuan Li, Yani Zhang, Yangqianwen Zhang, Jinxia Bao, Ji Hu, Siyun Shen, Zhao Yang, Jianmin Wu, Kaiting Wang, Yan Zhao, Shuai Yang, Shan Wang, Xinyao Qiu, Wenwen Wang, Xuan Wu, Hongyang Wang, Jin Gu & Lei Chen. (2021) Discovery of a Carbamoyl Phosphate Synthetase 1–Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis. Hepatology 74:6, pages 3249-3268.
Crossref
Crossref
Rasha M. Hassan, Mona E. Aboutabl, Manuela Bozzi, Mohammed F. El-Behairy, Ahmed M. El Kerdawy, Beatrice Sampaolese, Claudia Desiderio, Federica Vincenzoni, Francesca Sciandra & Iman A.Y. Ghannam. (2021) Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPARα agonists with anti-hyperlipidemic and antioxidant activities: Design, synthesis and in vitro/in vivo biological evaluation. Bioorganic Chemistry 115, pages 105170.
Crossref
Crossref
Donna D. Yu, Gregg Van Citters, Hongzhi Li, Brian M. Stoltz & Barry M. Forman. (2021) Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease. Bioorganic & Medicinal Chemistry 41, pages 116193.
Crossref
Crossref
Taohua Wei, Wenjie Hao, Lulu Tang, Huan Wu, Shi Huang, Yue Yang, Nannan Qian, Jie Liu, Wenming Yang & Xianchun Duan. (2021) Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan–Dou–Fu–Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model. Frontiers in Pharmacology 12.
Crossref
Crossref
Liwei Wu, Jingjing Li, Jiao Feng, Jie Ji, Qiang Yu, Yan Li, Yuanyuan Zheng, Weiqi Dai, Jianye Wu & Chuanyong Guo. (2021) Crosstalk between PPARs and gut microbiota in NAFLD. Biomedicine & Pharmacotherapy 136, pages 111255.
Crossref
Crossref
Kalina Duszka, András Gregor, Hervé Guillou, Jürgen König & Walter Wahli. (2020) Peroxisome Proliferator-Activated Receptors and Caloric Restriction—Common Pathways Affecting Metabolism, Health, and Longevity. Cells 9:7, pages 1708.
Crossref
Crossref
Justin Matheson & Bernard Le Foll. (2020) Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. Cells 9:5, pages 1196.
Crossref
Crossref
Emilia Gore, Emilia Bigaeva, Anouk Oldenburger, Yvette J. M. Jansen, Detlef Schuppan, Miriam Boersema, Jörg F. Rippmann, Andre Broermann & Peter Olinga. (2020) Investigating fibrosis and inflammation in an ex vivo NASH murine model. American Journal of Physiology-Gastrointestinal and Liver Physiology 318:2, pages G336-G351.
Crossref
Crossref
Waquar Ahsan. (2019) The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective. Current Pharmaceutical Design 25:23, pages 2540-2554.
Crossref
Crossref
Henriette Arnesen, Nadia Nabil Haj-Yasein, Jørn E. Tungen, Helen Soedling, Jason Matthews, Steinar M. Paulsen, Hilde I. Nebb, Ingebrigt Sylte, Trond Vidar Hansen & Thomas Sæther. (2019) Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist. Bioorganic & Medicinal Chemistry 27:18, pages 4059-4068.
Crossref
Crossref
Yan-Zhe Wang, He-Yu Zhang, Fang Liu, Lei Li, Shu-Min Deng & Zhi-Yi He. (2019) Association between PPARG genetic polymorphisms and ischemic stroke risk in a northern Chinese Han population: a case-control study. Neural Regeneration Research 14:11, pages 1986.
Crossref
Crossref
Elaina M. Maldonado, Ciarán P. Fisher, Dawn J. Mazzatti, Amy L. Barber, Marcus J. Tindall, Nicholas J. Plant, Andrzej M. Kierzek & J. Bernadette Moore. (2018) Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease. npj Systems Biology and Applications 4:1.
Crossref
Crossref
Benaïssa Boubia, Olivia Poupardin, Martine Barth, Jean Binet, Philippe Peralba, Laurent Mounier, Elise Jacquier, Emilie Gauthier, Valérie Lepais, Maryline Chatar, Stéphanie Ferry, Anne Thourigny, Fabrice Guillier, Jonathan Llacer, Jérome Amaudrut, Pierre Dodey, Olivier Lacombe, Philippe Masson, Christian Montalbetti, Guillaume Wettstein, Jean-Michel Luccarini, Christiane Legendre, Jean-Louis Junien & Pierre Broqua. (2018) Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. Journal of Medicinal Chemistry 61:6, pages 2246-2265.
Crossref
Crossref
Željko Reiner. (2018) Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. Korean Circulation Journal 48:12, pages 1097.
Crossref
Crossref
Tiziana Caputo, Federica Gilardi & Béatrice Desvergne. (2017) From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. FEBS Letters 591:19, pages 3061-3088.
Crossref
Crossref
Handong Niu, Wenbao Wang, Jinyan Li, Yu Lei, Yong Zhao, Weixu Yang, Chaoyue Zhao, Bin Lin, Shaojiang Song & Shaojie Wang. (2017) A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies. European Journal of Medicinal Chemistry 138, pages 212-220.
Crossref
Crossref
Olga Nikolaevna Styshova, Alexander Michailovich Popov, Alexander Alekseevish Artyukov & Anna Anatolievna Klimovich. (2017) Main constituents of polyphenol complex from seagrasses of the genus Zostera, their antidiabetic properties and mechanisms of action. Experimental and Therapeutic Medicine 13:5, pages 1651-1659.
Crossref
Crossref
Asti Jackson, Deniz Bagdas, Pretal P. Muldoon, Aron H. Lichtman, F. Ivy Carroll, Mark Greenwald, Michael F. Miles & M. Imad Damaj. (2017) In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence. Neuropharmacology 118, pages 38-45.
Crossref
Crossref
Cesar Sepúlveda, Iván Palomo & Eduardo Fuentes. (2017) Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. Vascular Pharmacology 91, pages 10-17.
Crossref
Crossref
Lorella Paparo, Antonio Calignano, Carlo G. Tocchetti, Carmen Di Scala, Roberto Russo, Domenico Bonaduce & Roberto B. Canani. 2017. Dietary Fiber for the Prevention of Cardiovascular Disease. Dietary Fiber for the Prevention of Cardiovascular Disease
61
71
.
Steven E. Gryn & Robert A. Hegele. (2016) New oral agents for treating dyslipidemia. Current Opinion in Lipidology 27:6, pages 579-584.
Crossref
Crossref
Paula MoralesPilar GoyaNadine JagerovicLaura Hernandez-Folgado. (2016)
Allosteric Modulators of the CB
1
Cannabinoid Receptor: A Structural Update Review
. Cannabis and Cannabinoid Research 1:1, pages 22-30.
Crossref
Crossref
Bogusław Okopień, Łukasz Bułdak & Aleksandra Bołdys. (2016) Current and future trends in the lipid lowering therapy. Pharmacological Reports 68:4, pages 737-747.
Crossref
Crossref
Michel Farnier. (2016) Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports 18:7.
Crossref
Crossref
Antonio Laganà, Salvatore Vitale, Angela Nigro, Vincenza Sofo, Francesca Salmeri, Paola Rossetti, Agnese Rapisarda, Sandro La Vignera, Rosita Condorelli, Gianluca Rizzo & Massimo Buscema. (2016) Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives. International Journal of Molecular Sciences 17:7, pages 999.
Crossref
Crossref
Germán Camejo. (2016) Selective PPAR modulators (SPPARs) may fill the need for treatment of the atherogenic dyslipidemia of insulin resistance and type 2 diabetes: Can they reduce the associated cardiac risk?. Atherosclerosis 249, pages 224-225.
Crossref
Crossref
A.M. Popov, O.N. Krivoshapko, A.A. Klimovich & A.A. Artyukov. (2016) Biological activity and mechanisms of therapeutic action of rosmarinic acid, luteolin and its sulphated derivatives. Biomeditsinskaya Khimiya 62:1, pages 22-30.
Crossref
Crossref
Salvatore Giovanni Vitale, Antonio Simone Laganà, Angela Nigro, Valentina Lucia La Rosa, Paola Rossetti, Agnese Maria Chiara Rapisarda, Sandro La Vignera, Rosita Angela Condorelli, Francesco Corrado, Massimo Buscema & Rosario D’Anna. (2016) Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions. PPAR Research 2016, pages 1-9.
Crossref
Crossref
Steven E. Gryn & Robert A. Hegele. (2015) Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology 26:6, pages 484-491.
Crossref
Crossref
Damon A. Bell & Gerald F. Watts. (2015) Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics 37:12, pages 2732-2750.
Crossref
Crossref
N. Fresno, M. Macías-González, A. Torres-Zaguirre, M. Romero-Cuevas, P. Sanz-Camacho, J. Elguero, F. J. Pavón, F. Rodríguez de Fonseca, P. Goya & R. Pérez-Fernández. (2015) Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry 58:16, pages 6639-6652.
Crossref
Crossref